ISB News

CRI iAtlas

CRI iAtlas Expands to Interactive Analysis of Data on Immunotherapy Treatments

CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors. 

Shmulevich-Thorsson

ISB Researchers Among Recipients of AACR Team Science Award

The American Association for Cancer Research (AACR) has recognized The Cancer Genome Atlas (TCGA) project with the 2020 AACR Team Science Awards. Award recipients include Dr. Ilya Shmulevich, ISB professor and head of the Shmulevich Lab; ISB senior research scientist Dr. Vésteinn Þórsson; and former Shmulevich Lab members Drs. Brady Bernard and Theo Knijnenburg.

ISB’s Computational Teams Play Central Role in Completion of TCGA’s PanCancer Atlas Initiative

ISB’s computational and bioinformatics teams played a central role in the completion of the PanCancer Atlas Initiative, the final phase of TCGA. The culmination of this work is being published in 27 papers this week across the Cell Press research journals, including “The Immune Landscape of Cancer” in Immunity.

CRI iAtlas

CRI, ISB, Sage Bionetworks Unveil Comprehensive Immunotherapy Tool

Three organizations on the forefront of cancer immunotherapy, systems biology and bioinformatics announced the release of the Cancer Research Institute iAtlas, a comprehensive web-based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment.

Comprehensive study of esophageal cancer reveals several molecular subtypes, provides new insight into increasingly prevalent disease

The Cancer Genome Atlas Research Network recommends clinical trials organizers and drug manufacturers focus on newly discovered molecular subtypes GRAND RAPIDS, Mich., Jan. 4, 2017 –– A comprehensive analysis of 559 esophageal and gastric cancer samples, collected from patients around the world, suggests the two main types of esophageal cancer differ markedly in their molecular characteristics and should be considered separate diseases. The study, published today in Nature from The…

ISB’s Role in TCGA

When you see a reference to “cancer research,” you know that it’s important. But do you really know what it means and how complex the research is? Many ISB scientists are entrenched in molecular cancer research. To better appreciate what they’re tackling, let’s talk about The Cancer Genome Atlas (TCGA) project. In understanding cancers, researchers first have to know what errors in the DNA of tumor cells cause them to…

ISB Co-Authored Nature Paper Featured in the New York Times

The Ilya Shmulevich Group at ISB has been participating in The Cancer Genome Atlas (TCGA) project as a Genome Data Analysis Center. The first paper resulting from the main phase of the TCGA project – "Comprehensive molecular characterization of human colon and rectal cancer" – was published in the July 19, 2012, issue of Nature and also featured on the front page of the New York Times. ISB teamed up…